We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel Solution Used to Store Donated Blood Platelets

By LabMedica International staff writers
Posted on 28 Dec 2009
A platelet additive solution, in combination with human plasma, is being used to store donated platelets, a vital blood component used to prevent or treat bleeding.

The InterSol additive is an isotonic solution designed to replace a portion of the plasma used in the storage of leuko-reduced apheresis platelets, under standard blood banking conditions. More...
The platelets can be stored in a mixture of up to 65% InterSol solution and 35% human plasma, which can then be used for other therapeutic purposes. There is no direct therapeutic effect to be expected from the formulation, and the solution should never be infused directly into a patient. The InterSol solution is provided as a 500 ml sterile and nonpyrogenic solution in a non-PVC plastic container, with a sterile fluid path. Platelets prepared with the solution may be stored for up to 5 days at 20 °C to 24 °C, with continuous agitation.

The solution contains constituents that are naturally occurring components present in many cellular systems: sodium acetate as a nutrient, sodium citrate to prevent platelet clumping and activation, sodium phosphate for buffering, and sodium chloride for osmolarity. The InterSol solution does not have a pharmacological effect in vivo, but rather acts to provide the appropriate environment and nutrients in lieu of a portion of the plasma normally used for the storage of platelets. The InterSol solution is a product of Fenwal Blood Technologies (Lake Zurich, IL, USA), and has been approved for use by the U.S. Food and Drug Administration exclusively with platelets collected using the Fenwal Amicus separator, a medical device that collects platelets and other blood components from eligible donors.

"FDA approval for the InterSol solution is an exciting milestone for Fenwal and represents our collaboration with customers, industry, and scientific leaders to introduce new ways to collect, process, and store blood for transfusion,” said William H. Cork, Fenwal senior vice president and chief technology officer (CTO).

Refrigerated platelets have better in vitro function than those stored at room temperature, but once transfused, they are rapidly cleared from the circulation. In 1981, platelet storage at room temperature was extended from 3 days to 5 days due to improved platelet storage bags that allowed more efficient gas exchange. However, with the extended storage at room temperature, bacterial proliferation became a significant problem and an increased number of platelet transfusion-associated sepsis reactions occur.

Related Links:
Fenwal Blood Technologies




New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.